Now showing items 1-3 of 3

    • Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer 

      Oxnard, Geoffrey Raymond; Paweletz, Cloud; Sholl, Lynette Marie (American Medical Association (AMA), 2016)
      The increased importance of cancer genotyping in guiding cancer treatment has created a need for efficient methods for genomic analysis of patients’ cancers. This increased dependence on DNA-based tumor genotyping assays ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression 

      Awad, Mark Magdi; Oxnard, Geoffrey Raymond; Jackman, David M; Savukoski, Daniel O.; Hall, Dimity; Shivdasani, Priyanka; Heng, Jennifer C.; Dahlberg, Suzanne Eleanor; Janne, Pasi Antero; Verma, Suman; Christensen, James; Hammerman, Peter Seth; Sholl, Lynette Marie (American Society of Clinical Oncology (ASCO), 2016)
      Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of ...